Anne F Eder1, Beth A Dy2, Barbara DeMerse2, Stephen J Wagner3, Susan L Stramer4, E Mary O'Neill2, Ross M Herron5. 1. Georgetown University School of Medicine, Washington, DC. 2. National Headquarters, Biomedical Services, Rockville, Maryland. 3. Holland Laboratory, Biomedical Services, American Red Cross, Rockville, Maryland. 4. American Red Cross Scientific Affairs, Gaithersburg, Maryland. 5. West Division, American Red Cross, Pomona, California.
Abstract
BACKGROUND: Apheresis technology to collect platelet (PLT) components differs among devices. We evaluated the relationship of the plateletpheresis device with bacterial contamination and reported septic transfusion reactions. STUDY DESIGN AND METHODS: Plateletpheresis was performed using Amicus (Fenwal, a Fresenius Kabi Company) or Trima (Trima Accel, TerumoBCT) from 2010 to 2014. All donations used inlet-line sample diversion and were tested by quality control (QC; Day 1) aerobic culture. Rates of bacterial contamination and septic reactions to PLTs were calculated for both devices. RESULTS: During the 5-year study period, plateletpheresis collections using Amicus and Trima devices totaled 1,486,888 and 671,955 donations, respectively. The rate of confirmed-positive bacterial cultures of apheresis PLT donations was significantly higher with Amicus than with Trima (252 vs. 112 per 106 donations [odds ratio {OR}, 2.3; 95% confidence interval {CI}, 1.8-2.9]). Septic transfusion reactions were caused by 30 apheresis PLT units from 25 contaminated Amicus procedures and three apheresis PLT units from three contaminated Trima procedures. The overall rate of septic reactions was significantly higher with apheresis PLT components collected with Amicus than with Trima (16.8 vs. 4.5 per 106 donations [OR, 3.8; 95% CI, 1.1-12.5]). All apheresis PLT components implicated in septic transfusion reactions had negative QC culture results incubated through Day 5 (i.e., false negatives). CONCLUSION: Apheresis technology affects bacterial contamination of plateletpheresis collections. The device-specific, higher rate of confirmed-positive bacterial culture results also correlated with a significantly higher rate of reported septic transfusion reactions to apheresis PLTs.
BACKGROUND: Apheresis technology to collect platelet (PLT) components differs among devices. We evaluated the relationship of the plateletpheresis device with bacterial contamination and reported septic transfusion reactions. STUDY DESIGN AND METHODS: Plateletpheresis was performed using Amicus (Fenwal, a Fresenius Kabi Company) or Trima (Trima Accel, TerumoBCT) from 2010 to 2014. All donations used inlet-line sample diversion and were tested by quality control (QC; Day 1) aerobic culture. Rates of bacterial contamination and septic reactions to PLTs were calculated for both devices. RESULTS: During the 5-year study period, plateletpheresis collections using Amicus and Trima devices totaled 1,486,888 and 671,955 donations, respectively. The rate of confirmed-positive bacterial cultures of apheresis PLT donations was significantly higher with Amicus than with Trima (252 vs. 112 per 106 donations [odds ratio {OR}, 2.3; 95% confidence interval {CI}, 1.8-2.9]). Septic transfusion reactions were caused by 30 apheresis PLT units from 25 contaminated Amicus procedures and three apheresis PLT units from three contaminated Trima procedures. The overall rate of septic reactions was significantly higher with apheresis PLT components collected with Amicus than with Trima (16.8 vs. 4.5 per 106 donations [OR, 3.8; 95% CI, 1.1-12.5]). All apheresis PLT components implicated in septic transfusion reactions had negative QC culture results incubated through Day 5 (i.e., false negatives). CONCLUSION: Apheresis technology affects bacterial contamination of plateletpheresis collections. The device-specific, higher rate of confirmed-positive bacterial culture results also correlated with a significantly higher rate of reported septic transfusion reactions to apheresis PLTs.
Authors: Sanjida J Mowla; Ian T Kracalik; Mathew R P Sapiano; Lynne O'Hearn; Chester Andrzejewski; Sridhar V Basavaraju Journal: Transfus Med Rev Date: 2021-04-02
Authors: John M Gansner; Mahboubeh Rahmani; A Helena Jonsson; Brooke M Fortin; Idayat Brimah; Martha Ellis; Robin Smeland-Wagman; Zhihan J Li; Jason M Schenkel; Michael B Brenner; Revital Yefidoff-Freedman; Steven R Sloan; Nancy Berliner; Nicolas C Issa; Lindsey R Baden; Dan L Longo; Duane R Wesemann; Donna Neuberg; Deepak A Rao; Richard M Kaufman Journal: Blood Date: 2018-11-14 Impact factor: 22.113
Authors: Richard R Gammon; Rita A Reik; Marc Stern; Ralph R Vassallo; Dan A Waxman; Pampee P Young; Richard J Benjamin Journal: Transfusion Date: 2021-12-20 Impact factor: 3.337
Authors: Roberta Z Horth; Jefferson M Jones; Janice J Kim; Bert K Lopansri; Sarah J Ilstrup; Joy Fridey; Walter E Kelley; Susan L Stramer; Ashok Nambiar; Lynn Ramirez-Avila; Amy Nichols; Wendy Garcia; Kelly F Oakeson; Nicholas Vlachos; Gillian McAllister; Robert Hunter; Allyn K Nakashima; Sridhar V Basavaraju Journal: MMWR Morb Mortal Wkly Rep Date: 2018-06-29 Impact factor: 17.586
Authors: Sydney A Jones; Jefferson M Jones; Vivian Leung; Allyn K Nakashima; Kelly F Oakeson; Amanda R Smith; Robert Hunter; Janice J Kim; Melissa Cumming; Eileen McHale; Pampee P Young; Joy L Fridey; Walter E Kelley; Susan L Stramer; Stephen J Wagner; F Bernadette West; Ross Herron; Edward Snyder; Jeanne E Hendrickson; David R Peaper; Adi V Gundlapalli; Charles Langelier; Steve Miller; Ashok Nambiar; Morvarid Moayeri; Jack Kamm; Heather Moulton-Meissner; Pallavi Annambhotla; Paige Gable; Gillian A McAllister; Erin Breaker; Erisa Sula; Alison Laufer Halpin; Sridhar V Basavaraju Journal: MMWR Morb Mortal Wkly Rep Date: 2019-06-14 Impact factor: 17.586
Authors: Emily Crawford; Jack Kamm; Steve Miller; Lucy M Li; Saharai Caldera; Amy Lyden; Deborah Yokoe; Amy Nichols; Nam K Tran; Sarah E Barnard; Peter M Conner; Ashok Nambiar; Matt S Zinter; Morvarid Moayeri; Paula Hayakawa Serpa; Brian C Prince; Jenai Quan; Rene Sit; Michelle Tan; Maira Phelps; Joseph L Derisi; Cristina M Tato; Charles Langelier Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079